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Available online 27 September 2014AbstractObjectives: Dental extractions in heart surgery patients treated with artificial mechanical heart valves under anticoagulant oral
therapy can be difficult as these patients present a significant risk for postoperative hemorrhagic complications. This study was
performed to evaluate the use of Platelet Rich Fibrin (PRF) and Hemcon dental dressing (HDD) in cardiac patients taking Warfarin
following dental extraction.
Methods: 20 patients were involved in this study with an age range of 36e62 years. Patients having an International Normalized
Ratio (INR) >3.5 were excluded. Extraction was performed under local anesthesia and as atraumatic as possible. Patients were
allocated equally in two groups; group A: where PRF was inserted into the extraction socket, while group B: the extraction socket
was packed by HDD.
Results: Complete hemostasis was achieved in all cases with no delayed bleeding. Patients in group A showed minimal pain and
accelerated healing, while those in group B showed extreme to moderate pain on the first few days following extraction and retarded
healing. Four patients developed alveolar osteitis.
Conclusions: PRF has good antihemorrhagic properties and increases tissue healing and wound closure, thus allowing for a quick
recovery without significant painful events. HDD has excellent hemostatic properties and can be used safely in such patients but
with small amounts.
© 2014, Production and Hosting by Elsevier B.V. on behalf of the Faculty of Dentistry, Tanta University.
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Dental extractions in heart surgery patients treated
with artificial mechanical heart valves under antico-
agulant oral therapy is difficult as these patients present
a significant risk for postoperative hemorrhagic com-
plications [1,2]. The most commonly prescribed oral
anticoagulants for these patients are warfarin and
acetylsalicylic acid. Therapeutic levels of warfarin arethe Faculty of Dentistry, Tanta University.
1 Marevan®, Glaxo, Egypt.
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(INR). The British Society of Hematology has pub-
lished guidelines on anticoagulant control which
recommend a maximum target INR of 3.5, with a range
of 3e4 [3].
Currently, many authors do not recommend sus-
pending the anticoagulant therapy and replacing it with
heparin injection intravenously or deep subcutaneous
before a minor surgery to avoid serious thromboem-
bolic complications [4]. To control the hemorrhagic
risk in patients under anticoagulant therapy, several
protocols have been proposed in the literature. Some
authors have recommended a combination of local
antifibrinolytic therapy and hemostatic agents for the
prevention of postoperative bleeding [5]. Other authors
have suggested that many patients can safely undergo
outpatient oral surgical procedures without changes in
their regular therapeutic anticoagulant regimen and
without additional medical interventions, or by using
the tranexamic acid as an antifibrinolytic local agent
for 2 days after the surgery [6e8]. While other in-
vestigators have proposed the sole use of fibrin glue to
prevent the hemorrhagic complications, however these
fibrin products are expensive and raise the question of
the potential for infectious contaminations [9e12].
The development of platelet concentrate technolo-
gies offers simplified and optimized production pro-
tocols for concentrated platelet-rich plasma (cPRP).
Because of legal restrictions on blood handling, a
second-generation platelet concentrate, which is
neither fibrin glue nor a classical platelet concentrate,
was developed in France by Choukroun et al., in 2001
[13]. The preparation of this relatively new biomate-
rial, called platelet-rich fibrin (PRF) requires neither
anticoagulant nor bovine thrombin. PRF is a strictly
autologous fibrin matrix containing a large quantity of
platelet and leukocyte cytokines and it is widely used
to accelerate soft and hard tissue healing. Autologous
PRF is considered as a healing biomaterial, which was
initially used in oral implantology by its promoters,
and presently, studies have shown its application in
various disciplines of dentistry [14].
On the other hand, chitosan preparations of various
molecular weights, degrees of deacetylation and with
further molecular derivatization patterns have attracted
much attention because of their potentially beneficial
biological properties. These properties include hemo-
stasis, antimicrobial activity, stimulation of healing,
tissue engineering scaffolds, and drug delivery
[15e22].
The HemCon Dental Dressing (HDD) has been used
extensively under the name HemCon Bandage to stopbleeding in combat wounds and other severe trauma.
HDD is a compressed chitosan acetate dressing that
was developed as a hemostatic agent [23e25]. HDD is
chitin, which is manufactured from freeze-dried
shrimp shells. It is an insoluble polysaccharide poly-
mer of glucosamine that is purified and partially
deacetylated to form soluble chitosan aqueous gel.
Chitosan gel is then freeze dried in molds to make a
highly electropositive sponge-like material that is he-
mostatic and adapts well to oral surgical wounds
[20,26]. Chitosan has a positive charge and attracts red
blood cells (RBC) and platelets, which are negatively
charged through ionic interaction; thus, a strong seal is
formed at the wound site. [25] This supportive, primary
seal allows the body to activate its coagulation pathway
effectively, initially forming organized platelets.
Therefore, HDDs are designed to maintain this seal
and serve as a frontline support structure as the plate-
lets and red blood cells continue to aggregate until
hemostasis is achieved [23,27].
Therefore, the purpose of this study was to test the
null hypothesis that there will be no difference in the
effectiveness of PRF and HDD in wound healing and
in the prevention of hemorrhagic complications after
dental extractions in patients receiving oral anticoag-
ulant therapy.
2. Materials and methods
This is a randomized clinical trial and was approved
by the institutional review board and the ethical com-
mittee of the Faculty of Dentistry, Alexandria Uni-
versity, and an informed consent was obtained from all
patients before their inclusion in the study.
This study was conducted on 20 patients referred to
the Oral and Maxillofacial Surgery department, Fac-
ulty of Dentistry, Alexandria University. All patients
were cardiac patients and had undergone heart valve
replacement and were currently taking Warfarin.1 They
required extraction of a single mandibular posterior
tooth. Extractions were performed for all patients
without altering the dose of the anticoagulant. Patients
who had an INR >3.5 on the day of operation or had a
history of liver disease or coagulopathies were
excluded from this study. The patients were randomly
divided into two groups: group A, where the extraction
sockets were packed with PRF, and group B, where the
extraction sockets were packed with HDD. The allo-
cation of patients into either group was random non-
blind as there was no way to mask the HDD group
Fig. 1. A pre-operative orthopantogram of a patient in group A
showing left mandibular third molar indicated for extraction.
Fig. 2. Left mandibular third molar indicated for extraction.
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the patient.
A full medical history was taken and an ortho-
pantogram and clinical examination were performed.
Antibiotic prophylaxis was given to all patients two
days pre-operatively, once a day, in the form of 875 mg
Amoxicillin and 125 mg Clavulanic acid.2 A pre-
operative INR was performed for all patients on the
day of extraction. If the INR was more than 3.5, the
patient was excluded from the study.
Local anesthesia, 2% lidocaine and 1:100,000
epinephrine was given to all patients using the inferior
alveolar nerve block technique and long buccal nerve
infiltration. Dental extractions were then performed as
atraumatic as possible, using extraction forceps and
elevators when needed. Immediately following
extraction, the sockets were packed with either PRF or
HDD.
Group A: (Ten patients)
20 ml of blood were collected without anticoagulant
from the brachial vein 12 min before extraction. The
blood was transferred and equally divided in two 10 ml
sterile glass tube, and was immediately centrifuged
using a table centrifuge at 3000 rpm for 12 min. The
absence of anticoagulant implies the activation of most
platelets in contact with the glass tube walls in a few
minutes and the release of the coagulation cascades.
Fibrinogen is initially concentrated in the high part of
the tube, before the circulating thrombin transforms it
into fibrin. A fibrin clot is then obtained in the middle
of the tube, just between the red corpuscles at the
bottom and acellular plasma at the top. The success of
this technique entirely depends on the speed of blood
collection and transfer to the centrifuge. Quick
handling is the only way to obtain a clinically usable2 Augmentin™ 1 gm, Egypt.PRF clot. After centrifugation, each PRF clot was
separated from the red blood cell base and placed
directly into the post-extraction sockets, and stabilized
by 3/0 silk suture (Figs. 1e7).
Group B: (Ten patients)
HemCon® dental dressing3 (HDD) 10 mm 12 mm,
was placed into the extraction sockets at the height of the
alveolar bone. Whenever needed, the dressing was
trimmed using a scissors to fit inside the sockets. Direct
finger pressure was then applied over the extraction site
for 40e60 s after placement of the HDD. No suturing
was done according to the manufacturers' recommen-
dations (Figs. 8e12).
The time of hemostasis was recorded for each pa-
tient using a stop watch. Antibiotics were continued
three days post-extraction in the form of 875 mg
amoxicillin and 125 mg clavulanic acid once a day.
Analgesics were prescribed every 8 h for 3 days in the
form of diclofenac potassium 50 mg.4 Post-extraction
sites were monitored daily for a week to assess po-
tential late hemorrhagic complications and to evaluate
pain and tissue healing. Relative pain scores were
evaluated using the Visual Analogue Scale (VAS) [28],
where 0 means no pain and 10 being the worst pain the
patient had ever experienced. Patients were also eval-
uated for alveolar osteitis. Sutures were removed one
week following extraction.3 HemCon medical technologies, Inc., Portland, USA.
4 Cataflam®, Novartis Pharma Company.
Fig. 3. Glass test tubes showing the 3 layers of the centrifuged blood.
Fig. 5. Placing the PRF clot inside the extraction socket.
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Twenty patients were involved in this study, 11
males (55%) and 9 females (45%). Their ages ranged
between 36 and 62 years (mean 46.65 years). All pa-
tients were under anticoagulant therapy using warfarin
due to: prosthetic heart valve (10 patients, 50%),
rheumatic heat disease (7 patients, 35%), or myocar-
dial infarction (3 patients, 15%). The INR of patients
ranged between 1 and 3.5 (mean ¼ 2.28; group
A ¼ 2.29 and group B ¼ 2.27) (Table 1 & Chart 1).
Complete hemostasis was achieved in all patients in
both groups. Regarding the time of hemostasis, there
was insignificant difference between both groups; in
group A, the mean time was 47.6 ± 1.3 s, while in
group B, the mean time was 51.3 ± 2.1 s. No post-
operative bleeding occurred in any patient in eitherFig. 4. The PRF clot.group on the day of extraction or on the following days
(Chart 2).
In group A, no cases of alveolitis were reported in
any patient, and there was no notable postsurgical pain
(VAS average 2, ranging between 1 and 3) on the 2nd
post-extraction day and 0 score on the following days.
Moreover, a quick healing of the extraction site was
already noted 2 days following extraction, and allFig. 6. The PRF clot placed inside the socket.
Fig. 7. PRF sutured in place.
Fig. 9. Left mandibular third molar indicated for extraction.
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tissue at the time of suture removal one week post-
extraction (Fig. 13).
While in group B, four cases reported severe pain
(VAS ¼ 8) in the first 48 h following extraction, which
was subsided gradually till the 7th post-extraction day,
due to the occurrence of alveolar osteitis. In those
patients, healing was not complete on the 7th post-
operative day and remnants of the HDD were seen in
the extraction sites (Fig. 14). Curettage was performed
and complete healing was observed on the 2nd post-
operative week. Two cases showed post-operative
pain of VAS 5 on the first two post-extraction days,
then decreased to 3 on the 3rd day and completely
disappeared on the 5th post-extraction day, complete
healing took place on the 10th post-extraction day. TheFig. 8. A pre-operative orthopantogram of group B showing left
mandibular third molar indicated for extraction.other four patients in group 2 showed minimal pain and
uneventful healing (Chart 2).
4. Discussion
All patients in this study were treated without
altering their anticoagulation medication regimens,
based on the evidence that the benefit of preventing
thromboembolism outweighs the risk of bleeding. The
current consensus recommends avoiding the interrup-
tion of anticoagulant therapy and preventing hemor-
rhagic complications by working with therapeutic INR
levels, and adopting local hemostatic measures [29].
In the study published by Sacco et al., in 2007 [30],
they revealed that there were no differences between
reducing the dose of the oral anticoagulant (OAC) or
maintaining the OAC dose with the use of local he-
mostatic measures in patients undergoing oral surgical
procedures.
On the other hand, not all authors agree with this
view and there are protocols that recommend inter-
ruption or reduction of OAC in the days prior to the
intervention to secure subtherapeutic INR levels
(INR < 2) in a short period of time before the operation
[31,32].
In this study we compared the effectiveness of the
PRF and the HDD in those patients. Both the PRF and
HDD have shown excellent hemostasis properties on
the time of extraction. Patients who were treated with
the PRF showed minimal pain and accelerated healing,
while those treated with the HDD showed extreme to
moderate pain on the first few days post-extraction and
Fig. 10. a, b The Hemcon dental dressing (HDD).
Fig. 11. HDD immediately after insertion in the extraction socket.
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nants of HDD in four patients.
During PRF processing by centrifugation, platelets
are activated and cytokines are released. Analysis of
the PDGF-BB, TGF-b1, and IGF-I within the PRF clot
exudate serum, revealed that slow fibrin polymeriza-
tion during PRF processing leads to the intrinsic
incorporation of platelet cytokines and glycanic chains
in the fibrin meshes, which allows for their progressive
release over time (7e11 days), as the network of fibrin
disintegrates. Moreover, during PRF processing, leu-
cocytes could also secrete cytokines in reaction to the
hemostatic and inflammatory phenomena artificially
induced in the centrifuged tube. This concept also
could explain the reduction of postoperative infections
when PRF is used as a surgical additive and the clin-
ically observed healing properties of PRF [13,33,34].
Therefore, the slow release of cytokines certainly
explains the immediate anti-hemorrhagic properties of
the PRF clot. Furthermore, in this study, no delayed
bleeding was reported, which is a significant problem
in patients under anticoagulant therapy. The slow
release of growth factors from the PRF membrane and
the strong fibrin architecture of the clot accelerate and
improve soft tissue and bone healing. As the wound
closure is accelerated, delayed bleedings are logically
avoided. Moreover, PRF is rich in leukocytes, and
these cells may be a significant asset for protecting the
surgical sites against local infections and associated
delayed healing [35,36].
These results are in accordance with other studies in
literature reporting the effect of PRF in wound healing.
Lundquist et al. [37] in 2013 and Jorgensen et al. [38]
in 2011 suggested that the L-PRF could be beneficial
for the healing of recalcitrant wounds due to the
Fig. 12. Hemostasis after 1 min of placing the HDD.
Pathology
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Chart 1. Showing etiology of anticoagulant therapy.
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Also, Chignon-Sicard et al. [39] in 2012 investigated
the efficacy of L-PRF in a randomized controlled
clinical trial of wound healing and demonstrated that a
single L-PRF application on fresh postoperative hand
wounds showed a median improvement of 5 days in
comparison with the standard treatment.
On the other hand, although the HDD sites showed
excellent hemostatic properties, we observed initial
raised pain scores. Also, four cases showed alveolar
osteitis, which may be due to the presence of remnants
of the HDD in the sockets, probably due to over
packing or deeply packing the material in the extrac-
tion sockets in the first few cases, resulting in retarded
dissolution of the material.
Hemcon is manufactured from freeze-dried chitosan
and molds to form a highly electropositive sponge-like
material. This charge facilitates blood clot formation
because it allows binding with red blood cells, which
are negatively charged, allowing the formation of an
extremely viscous clot that seals the wound site and
causes hemostasis. In addition, this property attracts
other chemotactic factors involved in the clotting
process. HDD material requires active bleeding; thus,
the more bleeding takes place, the better the HDD
material performs which is quite useful during surgical
procedures [27,40].
In the study performed by Malmquist et al. [27] in
2008, they also concluded that HDD has proved to be a
clinically effective hemostatic agent following oralTable 1
Showing sex, age and INR in both groups.
Group A (mean) Group B (mean)
Sex 6:4 5:5
Age 45.8 years ± 2.33 47.5 years ± 3.01
INR 2.29 ± 0.98 2.27 ± 0.71surgery procedures for all patients, including those
patients under anticoagulant therapy. The HDD ach-
ieved hemostasis in less than 1 min. On the other hand,
they stated that it had an improved surgical wound
healing capacity and that the pain scores and the
incidence of alveolar osteitis were lower for the HDD
treated sites, but they were not significantly different
than the control-treated sites, which is contradictory to
our results. In their study they used small amounts of
the HDD as they found out that if an excessive amount
of the material was used or if the extraction socket was
fully packed, small amounts of unreacted residual
acetic acid in the HDD would cause a minor transient
elevation in relative pain scores the first day or two
after surgery. This phenomenon may explain the
elevated pain scores in this study during the first two
days following extraction in the HDD group which
subsided once the acetic acid was fully dissolved in
oral fluids.
Shen et al. [41] in 2006 observed the enhancing
effects of chitosan on platelet adhesion and aggrega-
tion, as well as the release of growth factor from
human platelets stimulated by chitosan exposure,
which may help explain our positive findings regarding
hemostasis. In the study performed by Kale et al. [23]
in 2012, they stated that the sites that received the
HDD had improved postoperative healing with mini-
mal complications when compared to the control site.
They attributed their findings to the antibacterial
properties of chitosan as it increases the permeability
of the inner and outer membranes and ultimately dis-
rupts the bacterial cell membranes, releasing their
contents. Thus HDD provides an antibacterial barrier
against a wide range of Gram positive and Gram
negative organisms [42].
The results of this study could validate the use of
PRF during dental extractions for the prevention of
postoperative bleeding in patients on anticoagulant
therapy. The advantages of PRF are not only related to
its anti-hemorrhagic properties; PRF is also a filling
010
20
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60
Group A Group B
Time of hemostasis
Pain
Chart 2. Showing difference in pain and hemostasis levels between both groups.
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immune content may help protect the extraction
sockets against unavoidable infections, and by
enhancing soft tissue healing, PRF also reduces the
duration of the contamination of the surgical site byFig. 13. Healed extraction site after one week in group A.oral bacteria. With PRF filling, there are no side effects
and no significant discomfort nor painful events.
However, postoperative pain or discomfort was re-
ported by patients treated with HDD. Foreign materials
inserted within fresh extraction sockets always disturb
the healing process, whereas PRF, because it is a nat-
ural optimized blood clot, is completely tolerated.
5. Conclusion
The main advantage of PRF is its versatility: PRF
has good antihemorrhagic properties and increases
tissue healing and wound closure, thus allowing for a
quick recovery without significant painful events.
Many other applications of these antihemorrhagic and
healing properties could be tested and evaluated in
patients under anticoagulant therapy.Fig. 14. Extraction socket one week post-extraction showing rem-
nants of HDD in group B.
83R.M. Eldibany / Tanta Dental Journal 11 (2014) 75e84The HDD also has excellent hemostatic properties
and can be used safely in patients under anticoagulant
therapy, but with small amounts and avoid over-
packing the extraction sockets.
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